Last reviewed · How we verify
Pregabalin, Oxaliplatin
Pregabalin is a GABA receptor agonist, while oxaliplatin is a platinum-based DNA crosslinking agent.
Pregabalin is a GABA receptor agonist, while oxaliplatin is a platinum-based DNA crosslinking agent. Used for Neuropathic pain, Colorectal cancer.
At a glance
| Generic name | Pregabalin, Oxaliplatin |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | GABA receptor agonist, platinum-based DNA crosslinking agent |
| Target | GABA receptor, DNA |
| Modality | Small molecule |
| Therapeutic area | Pain, Oncology |
| Phase | Phase 3 |
Mechanism of action
Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death.
Approved indications
- Neuropathic pain
- Colorectal cancer
Common side effects
- Neuropathy
- Nausea
- Vomiting
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregabalin, Oxaliplatin CI brief — competitive landscape report
- Pregabalin, Oxaliplatin updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI